Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2009

View Archived Issues

Nitazoxanide increases early virological response rates in genotype 1 HCV patients

Neuren and the BCRT establish new company to target breast and other cancers

Experiments characterize CKD-516, a novel anticancer tubulin-binding agent

Saxagliptin improves glycemic control in diabetic patients as add-on or combination therapy

Olesoxime appears safe in spinal muscular atrophy patients

AEZS-112 safe, well tolerated in phase I trial in advanced cancer and lymphoma patients

Roche claims novel glucocorticoid receptor antagonists as antidiabetic agents

Servier presents novel compounds for the treatment of cardiovascular conditions

EMD-521873 shows safety in phase I trial in patients with advanced solid tumors

Novel antitumor compounds claimed by Merck & Co.

Novel oxadiazole derivatives for the treatment of autoimmune diseases claimed by Merck Serono

Aeras and Crucell initiate TB vaccine study in South African infants

Histone deacetylase inhibitors described by Merck & Co. for cancer treatment

BI-207127 monotherapy shows promising anti-hepatitis C virus genotype 1 activity in phase I trial

Cougar initiates phase III CB-7630 trial in castration-resistant prostate cancer

FDA grants orphan drug designation to Oncophage for glioma

FDA grants priority review to Xiaflex filing for Dupuytren's contracture

Genaera to liquidate assets and dissolve the company

Oxford BioMedica and sanofi-aventis to develop LentiVector-based ophthalmology drugs

Oxford BioMedica regains worldwide rights to cancer vaccine TroVax from sanofi-aventis

Alnylam and Isis sign licensing and collaboration agreement to develop ssRNAi technology

Enrollment completed in Rockwell Medical's phase IIb study of SFP in iron deficiency anemia

Genta provides update for late-stage progress of phase III Genasense trial

Stallergenes reports positive results from a phase IIb/III clinical trial

FDA approves BLA for Ipsen's Dysport in cervical dystonia and glabellar lines

ImQuest and Arisyn sign agreement to develop infectious disease and cancer drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...